Search clinical trials for: Telmisartan/Ramipril

Total 460 results

Institut de Recherches Cliniques de Montreal

Terminated

Higher Dose of Ramipril Versus Addition of Telmisartan-Ramipril in Hypertension and Diabetes

Hypertension | Type 2 Diabetes | Albuminuria

Canada
Boehringer Ingelheim

Completed

Bioequivalence of Telmisartan/g Ramipril Fixed Dose Combination Compared With the Monocomponents Telmisartan and Ramipril (Two Different Formulations) Given Concomitantly to Healthy Male and Female Volunteers

Healthy
Boehringer Ingelheim

Completed

Bioequivalence of Telmisartan / Ramipril Fixed Dose Combination Compared With the Monocomponents Given Concomitantly to Healthy Male and Female Volunteers

Healthy
Catholic University of the Sacred Heart

Unknown

Telmisartan Versus Ramipril After Acute Coronary Syndrome (TERACS)

Myocardial Infarction | Coronary Disease | Acute Coronary Syndrome

Italy
Postgraduate Institute of Medical Education and...

Completed

Efficacy of Telmisartan and the Combination of Telmisartan and Ramipril in type1 Diabetes Patients With Nephropathy (START1DM)

Diabetic Nephropathy

India
Novartis Pharmaceuticals

Completed

Compare the Effect of Aliskiren Plus Valsartan Versus Angiotensin-Converting Enzyme Inhibitor (ACEi) Plus Angiotensin Receptor Blocker (ARB) [Ramipril Plus Telmisartan] on the Renin-Angiotensin-Aldosterone System (RAAS) in Hypertensive Patients

Hypertension

Russian Federation
Boehringer Ingelheim

Completed

Effectiveness and Safety of Ramipril Alone Compared With Telmisartan Alone and in Combination With Ramipril in Patients at High Risk for Cardiovascular Events. Patients Intolerant to Ramipril Were Entered in TRANSCEND, Telmisartan Compared to Placebo.

Cardiovascular Diseases

United States, Argentina, Australia, Austria, Belgium, Brazil, Canada, China, Czech Republic, Denmark, Finland, France, Germany, Greece, Hong Kong, Hungary, Ireland, Italy, Korea, Republic of, Malaysia, Mexico, Netherlands, New Zealand and more
University of Erlangen-Nürnberg Medical School

Completed

TRENDY Follow-up: Study on Endothelial Function in Subjects With Type 2 Diabetes Mellitus

Type 2 Diabetes Mellitus

Germany
Boehringer Ingelheim

Completed

Influence of Food on the Bioavailability of Telmisartan / Ramipril Fixed Dose Combination in Healthy Male and Female Volunteers

Healthy
Boehringer Ingelheim

Completed

An Open-label, Long-term Study of Telmisartan Plus Amlodipine Fixed-dose Combination

Hypertension

Japan
Boehringer Ingelheim

Completed

Trial to Compare the Effects of Either Telmisartan (40-80 mg PO Once Daily) or Ramipril (5-10 mg PO Once Daily) on Renal Endothelial Dysfunction in Hypertensive Patients With Type 2 Diabetes

Hypertension | Diabetes Mellitus, Type 2

Germany, France, Spain
Boehringer Ingelheim

Completed

Prospective Randomised Investigation of the Safety and Efficacy of Micardis® vs Ramipril Using ABPM (PRISMA)

Hypertension

United Kingdom, Switzerland, Austria, France, Germany, Netherlands, South Africa, Spain
Boehringer Ingelheim

Completed

Telmisartan (Micardis) and Ramipril (Altace) - Factorial Design Study for the Treatment of Hypertension

Hypertension

United States, Argentina, Canada, Chile, Mexico, Peru
Boehringer Ingelheim

Completed

PROBE Investigation of the Safety & Efficacy of Telmisartan (Micardis®) vs Ramipril (Altace®) Using ABPM in HTN

Hypertension

United States, Canada
University of Michigan
Novartis Pharmaceuticals

Withdrawn

The Study of Novel Dual Renin Angiotensin Aldosterone System (RAAS) Blockade; Valsartan/Aliskiren in African American Patients With Hypertension and the Metabolic Syndrome (SAAVE)

Hypertension | Metabolic Syndrome

United States
Brigham and Women's Hospital

Completed

Replication of the ONTARGET Antihypertensive Trial in Healthcare Claims Data

Hypertension

United States
Novartis Pharmaceuticals

Completed

Effects of Aliskiren, Ramipril, and the Combination on Levels of Angiotensin II in Patients With Decompensated Systolic Heart Failure (ESCAPE-SHF)

Heart Failure

Russian Federation, Germany, Poland
Boehringer Ingelheim

Completed

Steady State Pharmacokinetics of Telmisartan, Ramipril or the Combination Following Repeated Oral Doses to Healthy Male and Female Volunteers

Healthy
Actavis Inc.

Completed

A Relative Bioavailability Study of Ramipril 10 mg Capsules Under Fed Conditions

Healthy

United States
Sandoz

Completed

To Demonstrate the Relative Bioavailability Study of Ramipril 10 mg Capsules Under Fasting Conditions

Hypertension
Emory University
National Institute on Aging (NIA)

Completed

Health Evaluation in African Americans Using RAS Therapy (HEART)

Alzheimer's Disease

United States
Boehringer Ingelheim

Completed

Bioequivalence of Telmisartan Film-coated Tablet Compared With the Conventional Telmisartan Tablet Following Oral Administration in Healthy Male Volunteers

Healthy
Boehringer Ingelheim

Completed

Evaluation of the Effect of Telmisartan on Blood Pressure Control of High Risk Patients

Hypertension

Romania
Gulhane School of Medicine

Completed

The Effect of Renin Angiotensin System Blockage (RAS) Blockade On PTX3 Levels In Diabetic Patients With Proteinuria

Diabetes | Proteinuria | Renin Angiotensin System

Turkey
Sandoz

Completed

To Demonstrate the Relative Bioavailability Study of Ramipril 10 mg Capsules Under Non-Fasting Conditions

Hypertension
Actavis Inc.

Completed

A Relative Bioavailability Study of Ramipril 10 mg Capsules Administered Orally as a Sprinkle on Applesauce

Healthy

United States
Boehringer Ingelheim

Completed

Effectiveness of MICARDIS® (Telmisartan) on Blood Pressure Control and Quality of Live in Patients With Essential Hypertension (MicCAT)

Hypertension
Boehringer Ingelheim

Completed

Bioequivalence of Telmisartan Film-coated Tablet Compared With Two Tablets of the Conventional Telmisartan Tablet in Healthy Male Volunteers

Healthy
Sanofi

Completed

An Open-label, Non-comparative Study to Document the Tolerability to Ramipril in Patients With at Least One High Risk for Developing a Major Cardiovascular Event (HOPETips)

Coronary Artery Disease

Indonesia
Boehringer Ingelheim

Completed

Natriuretic Effect of Telmisartan Versus Placebo in Patients With Mild-to-Moderate Hypertension

Hypertension
Actavis Inc.

Completed

A Relative Bioavailability Study of Ramipril 10 mg Capsules Under Fasting Conditions

Healthy

United States
Boehringer Ingelheim

Completed

INNOVATION Study - Telmisartan (Micardis) in Incipient Diabetic Nephropathy

Diabetic Nephropathies

Japan
Ranbaxy Laboratories Limited

Completed

Bioequivalence Study of Ramipril 10 mg Capsules Under Fed Conditions

Healthy

India
IlDong Pharmaceutical Co Ltd

Completed

Compare the Pharmacokinetics of TAH(80/10/12.5) Tablet in Comparison to the Co-administration of Telmisartan, Amlodipine and Hydrochlorothiazide in Healthy Male Volunteers

Healthy

Korea, Republic of
Boehringer Ingelheim

Completed

Efficacy and Safety of Telmisartan in Hypertensive Patients With Mild/Moderate or Severe Renal Impairment or Requiring Hemodialysis (ESPRIT)

Hypertension
Pfizer
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Treatment of Pediatric Hypertension With Altace Trial

Hypertension

United States
Pfizer

Terminated

A Study of the Effectiveness and Safety of Ramipril in the Treatment of Hypertension in Children and Adolescents

Hypertension

United States, Argentina, Colombia, India, Chile, Poland, South Africa, Turkey, Ukraine
Boehringer Ingelheim

Withdrawn

Comparison of the Medication Adherence of Patients Treated With Telmisartan/Hydrochlorothiazide or Telmisartan/Amlodipine Fixed Dose Combination (FDC) Versus Double-pill Combination Therapy in Real-world Japanese Therapeutic Practice

Hypertension

Japan
Laboratorio Elea Phoenix S.A.
Carlos R. Rojo, MD; Facultad de Medicina, Universidad de Buenos Aires, UBA

Completed

Telmisartan for Treatment of COVID-19 Patients

COVID-19 Drug Treatment

Argentina
Gulhane School of Medicine

Completed

Effect of Renin Angiotensin System Blockade on the Fas Antigen (CD95) and Asymmetric Dimethylarginine (ADMA) Levels in Type-2 Diabetic Patients With Proteinuria

Diabetic Nephropathy | Proteinuria | Chronic Kidney Disease

Turkey
Boehringer Ingelheim

Completed

Telmisartan in Mild to Moderate Hypertensive Patients

Hypertension
Medical University of Vienna

Completed

Gene Expression Profiling in Skeletal Muscle of Healthy Subjects Treated With Ramipril

Healthy

Austria
Bristol-Myers Squibb
Sanofi

Completed

Irbesartan Versus Placebo in Combination With Ramipril for Treatment of Albuminuria

Albuminuria

United States, Spain, Netherlands, Canada, Italy, Mexico, Israel, Australia, Russian Federation, United Kingdom, France, Germany, Latvia, Lithuania
Boehringer Ingelheim

Completed

Pharmacokinetics of Different Formulations of Telmisartan, Amlodipine, and Hydrochlorothiazide (HCTZ) in Japanese Healthy Male Volunteers

Healthy

Japan
HaEmek Medical Center, Israel

Recruiting

Explorative Study for Treating Persistent Developmental Stuttering With Ramipril

Persistent Developmental Stuttering

Israel
Stanford University
Cedars-Sinai Medical Center; VA Palo Alto Health Care System

Completed

Angiotensin Converting Enzyme (ACE) Inhibition and Cardiac Allograft Vasculopathy

Cardiac Allograft Vasculopathy

United States
Yuhan Corporation

Completed

Efficacy & Safety Study of YH22162 vs Telmisartan/Amlodipine in Patients With Hypertension Inappropriately Controlled on Telmisartan/Amlodipine Treatment

Hypertension

Korea, Republic of
Boehringer Ingelheim

Completed

Safety, Tolerability and Pharmacokinetics of Single Rising and Multiple Oral Doses of Telmisartan / Hydrochlorothiazide (HCTZ) in Healthy Male Volunteers

Healthy
Boehringer Ingelheim

Completed

Combination of Telmisartan 40 mg Plus Hydrochlorothiazide (HCTZ) 12.5 mg vs. Telmisartan 40 mg Alone in Patients With Essential Hypertension Who Fail to Respond Adequately to Telmisartan Monotherapy

Hypertension

Japan
Boehringer Ingelheim

Completed

Micardis®. Observational Study in Patients With Essential Hypertension

Hypertension

3

Subscribe